Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00234481 · ClinicalTrials.gov registry record · Phase 1

Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

A Phase 1 study, sponsored by Exelixis.

Terminated
Registry status
Phase 1
Development phase

NCT00234481 is a Phase 1 study that was terminated before completion, run by Exelixis.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00234481, a Phase 1 study, was terminated before completion, sponsored by Exelixis.

TERMINATED
Registry status
Phase 1
Development phase

Study Summary

The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Interventions

  • DRUG XL844

Trial Details

FieldValue
Phase Phase 1

Sponsor

Exelixis

48 total trials

What the Registry Record Tells You About NCT00234481

The ClinicalTrials.gov registry entry for NCT00234481 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which XL844 is the first listed.

NCT00234481 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00234481 about?

NCT00234481 is a clinical study titled "Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia". The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

What is the current status of trial NCT00234481?

This trial is currently terminated. It is a Phase 1 study.

What interventions are being tested in trial NCT00234481?

The interventions under investigation include: XL844 (DRUG).

Who is sponsoring clinical trial NCT00234481?

This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.